Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and nintedanib

erlotinib hydrochloride has been researched along with nintedanib in 3 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(nintedanib)		Trials
(nintedanib)		Recent Studies (post-2010) (nintedanib)
4,3537863,033846133801

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)nintedanib (IC50)
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.085
Tyrosine-protein kinase LckHomo sapiens (human)0.016
Tyrosine-protein kinase LynHomo sapiens (human)0.1483
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0133
Fibroblast growth factor receptor 1Homo sapiens (human)0.068
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.1093
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.017
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0395
Fibroblast growth factor receptor 2Homo sapiens (human)0.037
Fibroblast growth factor receptor 4Homo sapiens (human)0.61
Fibroblast growth factor receptor 3Homo sapiens (human)0.108
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)0.085
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0116
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)0.013
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.009
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.026
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.0026
Maternal embryonic leucine zipper kinaseHomo sapiens (human)0.043

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Klempner, SJ; Mills, GB; Myers, AP; Westin, SN1
Yaqub, F1
Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M1

Reviews

1 review(s) available for erlotinib hydrochloride and nintedanib

ArticleYear
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:16

    Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides

2013

Other Studies

2 other study(ies) available for erlotinib hydrochloride and nintedanib

ArticleYear
American Society of Clinical Oncology Annual Meeting 2013.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States

2013
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
    Journal of pharmaceutical and biomedical analysis, 2018, Sep-05, Volume: 158

    Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2018